About
As Head of Development, Jonathan is responsible for guiding the development of translational and clinical research strategies in collaboration with cross-functional research and development teams. In addition, he has played an instrumental role in helping to foster our productive collaboration with AbbVie.
Jonathan joined Calico in 2021 as Head of Oncology Research, overseeing our work on novel targets for cancer. He continues to run a research lab focused on defining new targets for inhibiting tumor growth and enhancing cancer immunotherapy.
Prior to joining Calico, Jonathan spent 20 years at Johns Hopkins University where, as a physician-scientist, his lab sought to understand how immune cells integrate signals from the immune micro-environment to promote differentiation and function. This work identified a critical role for mTOR in contributing to this process and focused on the metabolic programs that regulate immune responses to cancer.
Jonathan earned his Bachelor of Arts in Biochemistry from Dartmouth College and an M.D. Ph.D. in Immunology from the Emory University School of Medicine. He completed a residency at Johns Hopkins University followed by a clinical fellowship in hematology and oncology and Brigham and Women’s Hospital. He then went on to a post-doctoral fellowship in immunology in the lab of Ronald Schwartz at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. He is a board-certified oncologist.